Gopala Rangan is an academic nephrologist whose research focus is in developing treatments for kidney failure due to Autosomal Dominant Polycystic Kidney Disease (ADPKD) and generic forms of chronic kidney disease. He is Laboratory Head and Clinical Program Director in ADPKD (Western Sydney Renal Network) and undertakes a combination of preclinical and clinical trial research. He is Group Head of the Westmead PKD laboratory at the Westmead Institute for Medical Research.


Nephrology, Cell biology, Kidney disease, Pharmacology


Healthy Ageing

Clinical Specialty


Research Focus

Polycystic Kidney Disease, Chronic Kidney Disease, Glomerulonephritis

Other Affiliations

Faculty of Medicine and Health > Westmead Clinical School > Westmead Clinical School

Awards and Recognition

  • 1996-99 - Kidney Health Australia (KHA) Biomedical Scholarship
  • 1999-01 - Don and Lorraine Jacquot Post-Doctoral Fellowship
  • 1999-01 - BJ Amos Travelling Fellowship
  • 1999-01 - Australian and New Zealand Society of Nephrology (ANZSN) Fellowship
  • 1999-01 - Visiting Scientist, Division of Nephrology, University of Washington, Seattle, USA
  • 2001-04 - New Investigator Grant, National Health and Medical Council of Australia
  • 2010 - Basic Science Award, ANZSN
  • 2011-2014 - Member, Advisory Committee on the Safety of Medicines, TGA
  • 2012-19 - Member, Scientific Program and Education Committee, ANZSN
  • 2013-15 - Co-convener, ADPKD Clinical Practice Guideline Group, KHA-CARI Guidelines
  • 2014-17 - Member, Advisory Committee on the Safety of Medical Devices, TGA
  • 2014-current - Chair, Scientific Advisory Board, PKD Foundation of Australia



  • Cyclin Dependent Kinases As Drug-Targets To Reduce Renal Cyst Formation and Scarring in PKD.
  • Vitamin D3 receptor signalling to prevent kidney failure due to PKD.
  • NF-kappaB as a therapeutic target in PKD.
  • Controlled trial of slowing kidney disease progression from the inhibition of xanthine oxidase (CKD-FIX) (funded by NHMRC).
  • Randomised controlled trial to determine the safety and efficacy of prescribed water intake to prevent kidney failure due to ADPKD (PREVENT-ADPKD).  
  • Multi-centre, open-label, extension study to evaluate the long-term efficacy and safety of oral tolvaptan tablet regimens in subjects with ADPKD (REPRISE/TEMPO) (Otsuka).